Glyscend Therapeutics
Developer of oral, gut-targeted polymer therapeutics for the treatment of metabolic indications such as type 2 diabetes, and other chronic conditions. The company is developing a lead drug, which is orally administered, non-absorbed, gut-restricted duodenal exclusion therapy designed to replicate the metabolic effects of bariatric surgery with safety-advantages avoiding invasive complications of surgeries and procedures.
7-day free trial · no credit card
Verified contacts
5
available on Kipplo
LinkedIn employees
6
11 to 50 range
Open roles
—
no listings
Distinct roles
5
indexed titles
Tech stack
1
tools in use
Monthly traffic
24
organic / mo
Sign up free to see all 5 verified contacts at Glyscend Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
5 contacts with verified email or phone · masked until revealed.
- SS
Sapan Shah
Chief Executive Officer · General Business & Management
EmailPhone - CB
Christine Bryant
Sr Director of Clinical and Translational Science · Other
EmailPhone - KT
Karen Talmadge
Member, Board of Directors · General Business & Management
EmailPhone - BS
Bob Sacchiero
Independent Consultant · General Business & Management
EmailPhone - KC
Kevin Colbert
Biomedical Engineering Med Device Operations · Operations
EmailPhone
Showing 5 of 5 verified contacts
Top roles at Glyscend Therapeutics
5 distinct titles indexed · top 5 shown.
- 1biomedical engineering med device operations
- 1chief executive officer
- 1independent consultant
- 1member, board of directors
- 1sr director of clinical and translational science
Sign up to unlock all 5 contacts at Glyscend Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 5 verified contacts at Glyscend Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.